ALORA Drug Patent Profile
Which patents cover Alora, and when can generic versions of Alora launch?
Alora is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ALORA is estradiol. There is one drug master file entry for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alora
A generic version of ALORA was approved as estradiol by BARR LABS INC on October 22nd, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ALORA?
- What are the global sales for ALORA?
- What is Average Wholesale Price for ALORA?
Summary for ALORA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Patent Applications: | 4,105 |
| Drug Prices: | Drug price information for ALORA |
| What excipients (inactive ingredients) are in ALORA? | ALORA excipients list |
| DailyMed Link: | ALORA at DailyMed |
US Patents and Regulatory Information for ALORA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-004 | Apr 5, 2002 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-003 | Dec 20, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-001 | Dec 20, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALORA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-001 | Dec 20, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-004 | Apr 5, 2002 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | ALORA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020655-004 | Apr 5, 2002 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALORA
See the table below for patents covering ALORA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 167384 | ⤷ Start Trial | |
| Australia | 656755 | ⤷ Start Trial | |
| Australia | 9141391 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ALORA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0136011 | C00136011/03 | Switzerland | ⤷ Start Trial | PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417 |
| 0136011 | 2000C/027 | Belgium | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| 0136011 | 99C0003 | Belgium | ⤷ Start Trial | PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch